Compare Godaddy Inc (GDDY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Novartis AG — how do they compare? Godaddy Inc trades at $95.38 (market cap $12.09B), while Novartis AG trades at $152.79 (market cap $287.66B). The key difference: Novartis AG is far larger — about 23.8× Godaddy Inc's market cap, and Novartis AG pays a 3.14% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| GDDY | NVS | |
|---|---|---|
Market Cap | $12.09B | $287.66B |
Sector | Technology | Health |
52-Week High | $169.40 | $168.62 |
52-Week Low | $75.07 | $113.50 |
Enterprise Value | $14.67B | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $94.12, up 3.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 results due July 30, 2026. Fundamentals show robust profitability with a 17.32% net margin and 63.77% gross margin, though revenue growth is moderating. Analyst consensus is bullish with a $123 price target, but legal investigations pose sentiment risks.
Outlook remains positive given earnings momentum and high analyst buy ratings, but investors face near-term volatility from legal overhangs and elevated valuation multiples. The stock offers upside to consensus targets if execution continues, yet legal and competitive pressures require monitoring for sustained growth.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
